Highlights LSD1 is broadly associated with AR-regulated enhancers, and a subset is H3T6ph marked LSD1 is associated with CoREST at these sites and interacts with FOXA1
Correspondence ccai1@bidmc.harvard.edu (C.C.), hansenhe@uhnresearch.ca (H.H.H.) In Brief Cai et al. show that lysine-specific demethylase 1 (LSD1), although generally a transcriptional corepressor through H3K4 demethylation, functions broadly as a coactivator for androgen receptor and interacts with FOXA1 on androgenstimulated genes. LSD1-mediated H3K4 demethylation persists at these sites, indicating a distinct coactivator function mediated by demethylation of other substrates.
INTRODUCTION
Androgen receptor (AR) is highly expressed in prostate cancer (PCa) cells and plays a pivotal role in PCa through transactivation of multiple genes (Green et al., 2012; Yuan et al., 2014) . Patients with metastatic PCa are treated with androgen deprivation therapy (ADT) to block AR activity, but the tumors invariably relapse (castration-resistant prostate cancer [CRPC] ). Significantly, AR expression is increased in CRPC and most ARstimulated genes are highly expressed, indicating that AR transcriptional activity has been substantially restored (Yuan et al., 2014) . The recent clinical success of abiraterone (CYP17A1 inhibitor that further suppresses androgen synthesis) and enzalutamide (AR antagonist) has confirmed that AR, stimulated by residual androgens, is a driver of tumor growth in CRPC (de Bono et al., 2011; Ryan et al., 2013; Scher et al., 2012) . However, patients treated with these agents still generally relapse within 1-2 years, and high levels of AR and of ARregulated genes in many of these relapsed tumors indicate that AR activity has again been restored. Therefore, there is still a pressing need to better understand AR transcriptional mechanisms in order to develop further approaches for blocking or modulating its activity.
AR also has a transcriptional repression function that is dependent on lysine-specific demethylase 1 (LSD1, KDM1A) (Cai et al., 2011) . Best characterized as a transcriptional repressor, LSD1 associates tightly with CoREST and demethylates enhancerassociated H3K4me1,2 (Lee et al., 2005; Shi et al., 2004 Shi et al., , 2005 You et al., 2001) . The histone deacetylases HDAC1 and 2 are usually associated with the LSD1-CoREST complex and can further suppress gene transcription. Nonetheless, in contrast to its well-established corepressor function, LSD1 has been found to coactivate several transcription factors including AR on a small set of genes (Garcia-Bassets et al., 2007; Metzger et al., 2005; Wang et al., 2007a; Wissmann et al., 2007; Yatim et al., 2012) , where phosphorylation of H3T6 and H3T11 may switch LSD1 substrate specificity from H3K4me1,2 to H3K9me1,2 (Metzger et al., 2008 (Metzger et al., , 2010 . However, the extent to which LSD1 functions as a general regulator of AR transcriptional activities and the roles of histone phosphorylation and demethylation in mediating its AR coactivator function remain to be established. In this study, to systematically assess the role of LSD1 in regulating AR functions, we performed an integrated analysis with LSD1, AR, and FOXA1 chromatin immunoprecipitation sequencing (ChIP-seq), and with gene expression arrays. Our results demonstrate that LSD1 functions broadly as a coactivator at AR-stimulated enhancers but retains its H3K4me1,2 demethylase activity at these sites. This activity may provide negative feedback to suppress gene expression in the absence of androgen and prevent the aberrant activation of cryptic AR enhancers. Moreover, it indicates that androgen-dependent LSD1 coactivator function is mediated by demethylation of other histone or nonhistone substrates.
RESULTS

LSD1-Positive AR Binding Sites Are Associated with Androgen-Stimulated Genes
Using ChIP-seq for LSD1 in androgen-treated PCa cells (LNCaP), in combination with previous ChIP-seq data for AR and gene expression arrays (Cai et al., 2011; Lupien et al., 2008; Wang et al., 2007b Wang et al., , 2009b Yu et al., 2010) , we found that $20% of LSD1 and AR sites were overlapping ( Figure 1A ). AR binding sites were enriched $3-fold among genes that were increased after 4 or 16 hr of dihydrotestosterone (DHT) treatment, with $56% of DHT-stimulated genes having AR binding sites ( Figure 1B) . Similarly, LSD1 binding sites were enriched $2-fold among DHT-stimulated genes, with $42% having LSD1 binding sites ( Figure 1C ). AR binding was not clearly enriched among DHT-repressed genes ( Figure 1B ), whereas LSD1 binding was enriched $1.5-fold on these genes, and $29% had LSD1 binding sites (versus 20% background) ( Figure 1C ). However, direct examination of ChIP-seq data for LSD1-occupied sites in many DHT-repressed genes showed that AR was binding but was below the peak threshold ( Figure S1A ), possibly reflecting weaker AR binding or lower affinity of the antibodies for AR at these sites. LSD1 + as compared to LSD1 À AR binding sites were further enriched among DHT-stimulated genes ($5-to 7-fold versus $2-fold) ( Figure 1D ), and Binding and Expression Target Analysis (BETA) (Wang et al., 2013) confirmed that LSD1 + AR sites were significantly enriched for these genes ( Figure S1B ). Overall, among the genes stimulated by DHT after 4 hr that had AR binding sites ($56%), LSD1 was associated with the AR site at $39% (22%/56% Figure 1D ; Table S1 ). LSD1 binding intensity was similar between AR-positive and -negative sites ( Figures  S1C and S1D ), but AR-negative LSD1 sites were enriched in promoter regions ( Figure S1E ). Overall these findings showed that LSD1 was broadly associated with AR at androgen-stimulated genes.
LSD1 Functions as a Coactivator on a Large Fraction of AR-Stimulated Genes
Transcript profiling in LSD1 versus control small interfering RNA (siRNA)-treated cells next showed that LSD1-activated genes were enriched for cell-cycle and lipid synthesis pathways, whereas LSD1-suppressed genes were enriched for apoptosis ( Figure 1E ; Table S1 ). Significantly, androgen-stimulated genes were broadly decreased by LSD1 siRNA ( Figure 1F ). AR-positive LSD1 binding sites were also enriched for LSD1-activated genes, whereas AR-negative LSD1 binding sites were enriched for LSD1-suppressed genes ( Figure S1F ), consistent with LSD1 functioning generally as a corepressor at AR-negative sites, and indicating that its coactivation function is linked to AR. LSD1 inhibitors (pargyline and S2101) also impaired, but did not totally eliminate, androgen-stimulated expression of multiple AR-activated genes ( Figure 1G ), further indicating that LSD1 contributes to AR transcriptional activity but may not be absolutely required. AR + /LSD1 + sites in VCaP cells similarly showed enrichment for AR-stimulated genes, and LSD1 RNAi and inhibitors similarly decreased androgen-stimulated expression of these genes (Figures S1G-S1M). Finally, DNase sequencing (DNase-seq) (He et al., 2012) showed that AR +
/LSD1
+ sites were DNase hypersensitive (DNase-HS) and were more sensitive than AR + / LSD1 À sites ( Figure 1H ), further indicating these sites are ARregulated transcriptional enhancers. DNase-HS was increased by DHT at AR binding sites ( Figures 1H and S1N ), consistent with AR-mediated loss of a central nucleosome overlapping the AR binding site (Andreu-Vieyra et al., 2011; He et al., 2010) . Together these data indicated that whereas LSD1 is a corepressor at most sites, it functions broadly as a coactivator on AR-regulated transcriptional enhancers. Because the LSD1 transcription profiling indicated that LSD1 might both stimulate PCa growth through its AR coactivator functions and suppress apoptosis through AR-independent mechanisms, we examined whether LSD1 activity was increased in PCa. In three cohorts, expression of LSD1-activated genes (genes with LSD1 binding sites that were decreased by LSD1 siRNA) was increased in PCa versus normal prostate, whereas LSD1-suppressed genes were decreased ( Figure 1I ). Higher LSD1 mRNA also was significantly associated with lower survival in one patient cohort, whereas there was a similar trend in two other cohorts that did not reach statistical significance ( Figure S1O ).
LSD1 Mediates H3K4 Demethylation on AR-Stimulated Genes
To assess LSD1 effects on H3K4 and K9 methylation, we next examined AR + /LSD1 + binding sites in a series of AR-stimulated genes ( Figure S2A ). As expected, FOXA1 was bound to these sites prior to DHT treatment, and AR binding was stimulated by DHT ( Figure S2B ). FOXA1 and DHT-stimulated AR binding were also observed at AR
À sites (CREG1 and KIAA0040 genes), but not at AR À /LSD1 + sites in three other genes that were not androgen-regulated (HMGB2, HHLA3, SH2B1) ( Figure S2C ). DHT decreased H3K9me1,2 at each of the AR + /LSD1 + sites ( Figure S2D ), consistent with previous data indicating that LSD1 may switch from H3K4 to H3K9 demethylation at AR-regulated enhancers (Metzger et al., 2005 (Metzger et al., , 2008 (Metzger et al., , 2010 Wissmann et al., 2007) . However, H3K4me1,2 was also decreased by DHT at each AR + /LSD1 + site ( Figure S2D ), but Figure S2C , right panel), suggesting that LSD1 still had H3K4 demethylation activity at AR + /LSD1 + sites.
Consistent with previous data (Andreu-Vieyra et al., He et al., 2010) , ChIP showed that histone 3 (H3) binding was also decreased by DHT at each AR binding site ( Figure S2D ), indicating that the decrease in H3K4 and H3K9 methylation at AR + /LSD1 + sites may in part reflect loss of the central nucleosome rather than H3 demethylation. Therefore, to determine if decreased methylation reflects nucleosome loss, we next examined the effects of LSD1 inhibitors on AR and H3 binding, and on H3 methylation. Blocking LSD1 with pargyline prevented DHTstimulated H3K4me2 loss at all sites examined except the PLZF-ARE (Figure 2A , upper-left panel) but did not impair DHT-stimulated AR binding or H3 loss (Figure 2A , upper-right and lower-left panels). This result indicates that nucleosome loss does not substantially contribute to the overall decrease in H3K4me2 methylation, perhaps reflecting preferential loss of unmethylated central nucleosomes. LSD1 inhibition similarly impaired the DHT-stimulated decrease in H3K9me1, although it had varying effects on basal H3K9me1 (Figure 2A , lower right panel). Significantly, pargyline also increased H3K9me1 at AR-negative LSD1 sites, including REST sites where LSD1 functions as a corepressor, indicating that H3K9 demethylation by LSD1 may not be unique to ARstimulated genes ( Figure S2E ). Another LSD1 inhibitor (S2101) ( Figure S2F ) or LSD1 siRNA ( Figure S2G ) similarly did not impair AR binding, and comparable results for AR, H3, H3K4me2, and H3K9me1 were also obtained in VCaP cells with transient or stable knockdown of LSD1 ( Figures S2H and S2I) . Collectively, these results show that LSD1 retains its H3K4 demethylation activity at these AR-regulated enhancers.
We next used ChIP-seq to globally assess H3K4me2 in response to DHT (He et al., 2010 Figure 2D ). Interestingly, DHT caused a reduction of LSD1-CoREST binding at many of these sites, possibly reflecting subsequent chromatin remodeling. Significantly, CoREST siRNA mimicked the effects of LSD1 siRNA in decreasing expression of AR-stimulated genes ( Figure 2E ), further supporting a coactivator function for the LSD1-CoREST complex.
H3T6ph-Positive AR/LSD1 Sites Are Markedly Enriched for Androgen-Stimulated Genes Although these data indicated that LSD1 generally retains its H3K4 demethylase activity at AR-regulated enhancers, this activity may be impaired by H3T6ph at a subset of sites (Metzger et al., 2005 (Metzger et al., , 2008 (Metzger et al., , 2010 and 3B). Significantly, although only a minority of DHT-stimulated genes had H3T6ph-positive AR sites (14%-20%), these H3T6-positive sites were markedly enriched ($12-fold) for DHT-stimulated genes ( Figure 3C ). Moreover, H3T6ph-positive AR + /LSD1 + sites were even further enriched for DHT-stimulated genes ($18-fold) ( Figure 3D ). Finally, consistent with a previous report that androgen stimulates H3T6 phosphorylation through activating PKCb1 (Metzger et al., 2010) , treating cells with a Figure S1 and Table S1 .
PKCb inhibitor (BIM1) blocked the DHT-stimulated increase in H3T6ph and impaired the DHT stimulation of a panel of AR-regulated genes ( Figures S3A and S3B ). Together these findings indicate that H3T6 phosphorylation is linked to LSD1 coactivation of AR transcriptional activity. DNase-HS also was increased at H3T6ph-positive versusnegative AR + /LSD1 + sites ( Figure 3E ), further linking H3T6ph to transcriptional activation. In contrast, DNase-HS at H3T6-positive AR + /LSD1 À sites was low ( Figure 3E , right panel), whereas
DNase-HS at H3T6ph-positive versus -negative LSD1 sites was increased ( Figure S3C ), further supporting a link between LSD1 and H3T6ph. Similarly to DNase-HS, basal (prior to DHT stimulation) H3K4me2 was increased at H3T6ph-positive versus -negative AR + /LSD1 + sites ( Figure 3F ). However, DHT still caused a decrease in H3K4me2 methylation at these sites, versus an increase at LSD1-negative AR +
/H3T6ph
+ sites ( Figure 3F ). The
DNase-HS and H3K4me2 ChIP-seq data are quantified in Figures  S3D and S3E. We also assessed H3T6ph and H3K4me2 demethylation at a series of individual AR + /LSD1 + sites. These sites in four of six genes had high H3T6ph (PSA, NKX3.1, PLZF, and SGK3) ( Figure S3F ), but all underwent H3K4me2 demethylation in response to DHT (see Figure 2A) . Finally, inhibition of H3T6 phosphorylation with BIM1 did not enhance the androgen-stimulated demethylation of H3K4 or impair the demethylation H3K9 ( Figure S3G ). Together, these findings indicate that H3T6ph does not abrogate H3K4 demethylation by LSD1.
FOXA1 Associates with LSD1 and Mediates Its Recruitment to AR-Dependent Enhancers
As FOXA1 is a pioneer factor for AR-regulated enhancers, we next performed FOXA1 ChIP-seq and found substantial overlap ($42%) between LSD1 and FOXA1 sites ( Figure 4A ). 
/LSD1
+ sites ( Figure 4C ), consistent with the FOXA1-positive sites being enhancers, although DHT increased DNase-HS at all sites ( Figure S4B ). Coimmunoprecipitations in LNCaP cells indicated an association between FOXA1 and the LSD1-CoREST complex ( Figure 4D ). This was not mediated by AR, as we could also coprecipitate FOXA1 with transfected FLAG-LSD1 in AR-negative PC3 cells, although the interaction could still be indirect and through another protein or long noncoding RNA ( Figure 4E ). We next used FOXA1 siRNA to determine whether basal (prior to DHT treatment) LSD1 binding to AR +
/FOXA1
+ sites in ARregulated enhancers was FOXA1 dependent. Immunoblotting confirmed that FOXA1 siRNA markedly decreased FOXA1, but not LSD1 or CoREST ( Figure 4F) . Significantly, ChIP then showed that FOXA1 siRNA decreased basal LSD1 binding to a similar extent as CoREST siRNA at a series of AR/LSD1-regulated enhancers ( Figure 4G ). In the converse experiment, we treated cells with LSD1 siRNA and found a marked decrease in FOXA1 binding at these enhancers ( Figure 4H ). Collectively, these results indicate that FOXA1 may initially recruit the LSD1-CoREST complex to androgen-regulated enhancers, where FOXA1-LSD1 interactions may then stabilize the binding of both proteins to chromatin. The LSD1-CoREST complex may then function through HDACs to suppress basal transcription, and by H3K4 demethylation as a negative-feedback mechanism to close any aberrantly opened cryptic enhancers. Indeed, we found that HDAC1 and 2, which are components of the LSD1-CoREST complex, are associated with AR-regulated enhancers even in the absence of AR (Figure S4C) , and that HDAC inhibition increased basal expression of AR-stimulated genes ( Figure S4D ). Two recent studies found that FOXA1 RNAi caused a marked redistribution of AR, with loss of AR binding at many sites and generation of new binding sites (Sahu et al., 2011; Wang et al., 2011) . Using these data in conjunction with our AR and LSD1 ChIP-seq data, we found that $60% of AR binding sites were lost after FOXA1 knockdown, but that this loss was only 39% for the LSD1-positive AR binding sites ( Figure S4E ). Moreover, AR binding prior to FOXA1 siRNA was higher at the 61% of LSD1-positive AR sites that were retained versus the 39% that were lost, and AR binding at these 61% retained sites increased after FOXA1 siRNA ( Figure S4F ). H3K4me1 and H3K4me2 were also decreased after FOXA1 siRNA at these 61% of sites with retained/increased AR binding ( Figure S4F ). In conjunction with the above results, these findings suggest that LSD1 may stabilize AR binding directly, or indirectly through enhanced binding of residual FOXA1. Although we found that short-term inhibition or depletion of LSD1 did not impair AR binding (see Figures 2 and  S2) , we are currently exploring the long-term effect of LSD1 silencing on AR binding and enhancer activity through FOXA1-dependent or -independent mechanisms.
DISCUSSION
The H3K4me1,2 demethylase activity of LSD1 in LSD1-CoREST repressor complexes is well established, but LSD1 also can mediate H3K9me1,2 demethylation and function as a coactivator for several AR-stimulated genes (Metzger et al., 2005; Wissmann et al., 2007) , and an H3T6 and T11 phosphorylation-mediated switch from H3K4 to K9 demethylation may contribute to this LSD1 coactivator function (Metzger et al., 2008 (Metzger et al., , 2010 . This study shows that LSD1 is broadly associated with AR-regulated enhancers and functions as a coactivator for AR at these sites, and that H3T6ph-positive AR + /LSD1 + sites are further enriched for AR-activated genes. However, H3K4me2 ChIP studies showed that androgen-stimulated H3K4 demethylation persisted at AR + /LSD1 + sites, including H3T6ph-positive AR + /LSD1 + sites.
Moreover, LSD1-mediated H3K9 demethylation could also be observed at AR-independent LSD1 sites. Therefore, whereas some bias in favor of H3K9 versus H3K4 demethylation may contribute to LSD1 coactivator function, these findings indicate that LSD1 has dual corepressor and coactivator functions at androgen-stimulated genes, with the latter coactivator function being mediated by demethylation of additional nonhistone substrates. (legend continued on next page) H3K4 methylation and FOXA1 binding serve to initially expose enhancer binding sites prior to ligand-stimulated binding of steroid receptors (Carroll et al., 2005; Lupien et al., 2008) . This study shows that FOXA1 interacts with the LSD1-CoREST complex and may mediate its initial recruitment to AR-regulated enhancers. Conversely, LSD1 binding at these sites can then stabilize FOXA1 binding. LSD1 may then mediate demethylation of H3K4me2 at these sites as a negative-feedback mechanism to close enhancers if their H3K4 methylation and FOXA1 binding is not reinforced by AR, thereby preventing aberrant enhancer activation. AR may reinforce FOXA1 binding through a direct interaction, and indirectly by recruitment of H3K4 methyltransferases and HATs, the latter which may impair LSD1 activity through H3 acetylation. Finally, HDACs associated with the LSD1-CoREST complex may also serve to suppress gene expression prior to androgen stimulation and AR binding.
We hypothesize that the AR coactivator function of LSD1 reflects demethylation of one or more nonhistone substrates, but the identity of any novel LSD1 substrates and the functional consequences of their demethylation remain unclear. Mass spectrometry has identified methylated lysines in AR, but there are no data showing that they are regulated by LSD1 (Gaughan et al., 2011; Ko et al., 2011) . Recent studies have identified nonhistone LSD1 substrates, including transcription factors, but none are known to have roles in AR-mediated transcription (Cho et al., 2011; Huang et al., 2007; Kontaki and Talianidis, 2010; Wang et al., 2009a) . LSD1, possibly through interactions with long noncoding RNA, may also contribute to the targeting of AR-stimulated genes to specific nuclear domains that are enriched in transcriptional cofactors (Hu et al., 2008) . Importantly, our data show that inhibiting or depleting LSD1 acutely does not prevent AR binding to chromatin or displacement of the central nucleosome overlapping the AR binding site, indicating that any critical LSD1 substrates are functioning downstream of these initial steps. Identification of these substrates may allow for the selective abrogation of LSD1 coactivator function and provide a novel approach for PCa therapy.
EXPERIMENTAL PROCEDURES
RT-PCR, Immunoblotting, and Coimmunoprecipitation Quantitative real-time RT-PCR amplification was done with TaqMan one-step RT-PCR reagents and results were normalized to coamplified 18S RNA or GAPDH. For immunoblotting, cells were lysed with RIPA buffer with protease inhibitors. For immunoprecipitation assay, equal amounts of protein (1-5 mg) were mixed with 20-50 ml of antibody-conjugated agarose beads. Antibodies, primers, and probes are listed in Supplemental Experimental Procedures section. Gels shown are representative of at least three independent experiments.
Chromatin Immunoprecipitation
Cells were formalin fixed, lysed, and sonicated to break the chromatin into $500 bp fragments. ChIP-grade antibodies were used to precipitate chromatin fragments from cell extracts. We used real-time quantitative PCR (SYBR green) to amplify the DNA fragment in the antibody precipitated DNA and the unprecipitated input DNA to calculate the percentage. ChIP-seq was done with higher intensity sonication of cell lysates and sequenced with Illumina Genome Analyzer or High-seq. Significantly (p < 1 3 10 À5 ) enriched regions were detected using MACS. For all integrated analyses, we searched binding sites around 20 kb from transcriptional starting site.
Statistical Analyses
Data in bar graphs represent means ± SD of at least three biological repeats. Statistical analysis was performed by Student's t test. A p value < 0.05 was considered to be statistically significant.
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